Covid vaccine adverse effects: The European Medicines Agency (EMA) has issued a warning about three additional side effects.


THE SIDE effects of the Covid vaccines continue to be monitored stringently as booster programmes get underway. The European Medicines Agency (EMA) today has issued instructions to healthcare professionals administering the Janssen vaccine, which is approved for UK use. The EMA urges professionals to stay “alert” to three serious side effects following vaccination.

The vaccination rollout has been a largely successful experiment, inoculating much of the world against COVID-19. Like any new experiment, the side effects of getting vaccinated are recorded as vaccines make their way into new arms. Although the pros far outweigh the cons, it is incumbent on regulatory authorities to publish advice on the COVID-19 vaccines as new side effects come to light.

The latest vaccine to come under the microscope is the Janssen vaccine, which is expected to be made available in the UK later this year.

The European Medicines Agency (EMA) has issued important instructions to healthcare professionals in charge of dispensing the vaccine.

According to the EMA, cases of immune thrombocytopenia (ITP), some with very low platelet levels, have been reported very rarely, usually within the first four weeks after receiving COVID-19 Vaccine Janssen.

ITP is a disorder that can lead to easy or excessive bruising and bleeding.

The bleeding results from unusually low levels of platelets — the cells that help blood clot.

“This included cases with bleeding and cases with a fatal outcome. Some of these occurred in individuals with a history of ITP,” warns the EMA.

According to the regulatory body, individuals should “be alert to signs and symptoms of ITP, such as spontaneous bleeding, bruising or petechiae”.

Petechiae are pinpoint, round spots that appear on the skin as a result of bleeding.


“Individuals diagnosed with thrombocytopenia within three weeks after vaccination with COVID-19 Vaccine Janssen should be actively investigated for signs of thrombosis to assess a potential diagnosis of thrombosis with thrombocytopenia syndrome (TTS) that requires specialised clinical management,” according to the EMA statement.

Also, “if an individual has a history of ITP, the risks of developing low platelet levels should be considered before vaccination, and platelet monitoring is recommended after vaccination”, advises the health body.

It is important to underscore that the risk of serious complications in the general population remains vanishingly small.

Extensive evidence has found COVID-19 vaccines to be safe and effective for most recipients.

They give you the best protection. “Brinkwire Summary News”.


Comments are closed.